Co-Diagnostics and ReadyGo have begun feasibility work combining portable blood sample preparation with the Co-Dx PCR platform, using decentralized Ebola detection as the first test case.
Co-Diagnostics has completed the first international deployment of its Vector Smart mosquito surveillance platform, supplying an overseas U.S. Air Force base with local molecular testing and mosquito-abatement materials.
CoSara begins India clinical studies of Co-Diagnostics’ rapid tuberculosis PCR test, but assay clearance and real-world validation remain ahead.
Saudi localization gives Co-Diagnostics a new opening. The test is whether CoMira can turn a factory lease into diagnostics traction.
Co-Diagnostics, Inc. has received its first international patent for its Co-Dx PCR platform, with the Australian Patent Office granting coverage for the point-of-care molecular diagnostics system, including its PCR Pro instrument and disposable test cups. This development marks a critical step in the U.S.-based company’s international intellectual property strategy as it advances toward global commercialization